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Summary
Multiple chemical sensitivity (MCS) is a condition characterized by a subjectively 
perceived increase in sensitivity to environmental chemicals. Individuals affected re-
port a wide variety of nonspecific complaints, and frequently attribute cutaneous 
and mucosal symptoms to chemical exposures. Dermatologists should therefore be 
familiar with this condition. MCS is a diagnosis of exclusion. Other causes for the 
patients’ symptoms should be ruled out by routine laboratory tests, allergy tests 
and, if indicated, monitoring for toxic (environmental) substances. The primary job 
of dermatologists is to rule out skin diseases or hypersensitivities as possible cau-
ses of the complaints. Interdisciplinary patient management is essential, especially 
in severe cases in which those affected have problems coping with everyday life. 
Relevant specialties in this context include environmental medicine, psychoso-
matic medicine as well as occupational and social medicine. Cutaneous symptoms 
are usually addressed with symptomatic treatment using basic skin care products. 
There are currently no evidence-based treatment recommendations for MCS. It is 
crucial that MCS patients be protected from unnecessary treatments and thus from 
mental, social and financial strain. In addition to medical skills, managing MCS pati-
ents requires communicative and psychosocial competence in particular. Physicians 
involved in the treatment will benefit from training in psychotherapy. Irrespective 
of the mechanisms that lead to MCS, diagnosis and treatment of this condition re-
quire an actively supportive attitude towards these patients, a good doctor-patient 
relationship and interdisciplinary cooperation.
Introduction
Patients with multiple chemical sensitivity (MCS, also referred to as “idiopathic 
environmental intolerance”) describe themselves as “canaries” [1]. Similar to the 
birds previously used to warn coal miners of carbon monoxide (CO), as they would 
stop whistling in the presence of even small CO levels, individuals with MCS 
respond particularly sensitively to perceptible environmental substances.
Symptoms
Patients with MCS present with nonspecific symptoms following exposure to a 
wide range of environmental substances and noxious agents. In Germany, these 
substances include wood preservatives, solvents, insecticides, heavy metals, di-
sinfectants and fragrances [2]. Symptoms such as pruritus or a burning sensation 
of the skin, dry mouth, fatigue, dyspnea or anxiety are triggered by very low 
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levels that otherwise cause no reaction in healthy individuals [3]. Given the large 
interindividual differences in threshold levels, there are no generally accepted 
values.
Pathogenesis
Medical examination of MCS patients shows no specific trigger for their symp-
toms. The objective findings do not support the patients’ self-diagnosis and are 
therefore inconsistent with their subjective well-being. Affected individuals fre-
quently develop symptoms to multiple chemically unrelated, predominantly syn-
thetic substances. Very rarely, patients may also present with a diffuse clinical 
picture in which their symptoms are triggered by multiple natural and anthropog-
enic environmental agents. Our own experience shows that this primarily occurs 
in patients with long-standing or advanced disease. The exact pathomechanisms 
resulting in clinical symptoms following exposure to a given trigger are currently 
unknown.
Proposed hypotheses on the pathogenesis of MCS include aspects such as clas-
sical conditioning [4, 5], negative affect [6], physical stress reactions [7], cultural 
imprinting [8, 9], toxicant-induced loss of tolerance [10] and altered central pro-
cessing of stimuli [11–13]. A multifactorial model has also been proposed [14]. In 
particular, it remains unclear whether MCS is primarily a psychosomatic condition 
in which mental factors precede the physical complaints. On the other hand, it may 
also be possible that MCS is primarily a somato-psychological disorder in which 
somatic processes (e.g., conditioning) occur prior to the mental sequelae. Accor-
ding to the biopsychosocial disease model, MCS may also represent a “circular”, 
dynamic condition characterized by the interaction of psychosocial, ecological and 
biological processes (see Fuchs [15] or Egger [16]). Only the definitive elucidation 
of the underlying pathophysiology will show whether MCS is primarily a psycho-
somatic, somato-psychological or “circular” condition. Given these uncertainties, 
some MCS patients advocate for more research into the effects of chemicals on 
humans and for a reduction in the use of chemical agents in everyday life. This 
includes dedicated online forums [17].
Epidemiology
As MCS is characterized by subjective symptoms and is diagnostically challenging, 
the prevalence of this disorder is difficult to estimate. In 2005, a nationwide Ger-
man survey was conducted to obtain epidemiological data on subjective (multiple) 
chemical sensitivity [18]. Overall, 2,032 individuals > 15 years were surveyed. Nine 
percent of the respondents attributed their complaints to chemical exposures [18]. 
The condition was particularly common among women and above-45-year-olds 
[18]. The self-reported prevalence of medically diagnosed MCS in the total sample 
was 0,5 % [18]. Despite the difficulties in arriving at a good estimate of the pre-
valence of MCS, the available data suggests that more than 300,000 adults may 
possibly be affected in Germany. While the prevalence of self-reported chemical 
sensitivity is comparable to other Western societies (e.g., USA), the medical diagno-
sis of MCS is considerably less common in Germany. Possible reasons may include 
skepticism towards the diagnosis or lack of familiarity with this syndrome on the 
part of German physicians [18]. However, there may also be actual differences 
between various countries, for example, in terms of genetic disposition, chemical 
exposures or public perception [18].
MCS refers to a condition in which 
affected individuals develop nons-
pecific symptoms following expo-
sure to very low levels of (primarily 
anthropogenic) environmental agents.
Medical examination of MCS patients 
shows no specific trigger for their 
symptoms.
The pathomechanisms involved in MCS 
are currently unknown.
The prevalence of MCS is estimated at 
approximately 0.5 %.
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Psychosocial situation of affected individuals
Apart from physical complaints, individuals with MCS are commonly burdened 
by their psychosocial situation, and their quality of life is significantly impaired. 
Patients frequently feel stigmatized and not taken seriously [19]. In addition, many 
of those affected by MCS are no longer able to work or participate in public life due 
to their condition [20]. Mental disorders are very common among MCS patients, 
with nearly 80 % thereof being affected [21]. The presence of additional subjective 
somatic symptoms allows for the distinction between MCS and genuine psychiatric 
diseases [22].
Relevance of MCS for dermatologists
Given that environmental factors are responsible for triggering the symptoms in 
patients with MCS, the condition is considered an environmental disease. The 
skin is a barrier between humans and their environment, which is why MCS 
patients frequently attribute any cutaneous symptoms to their disorder. Uncle-
ar skin findings require a diagnostic workup. Allergic diseases should be ruled 
out. This practical guide is intended to assist dermatologists in the management 
of patients with MCS. We will discuss whether and how MCS can be diagno-
sed and treated, and address general aspects to be observed when managing 
MCS patients.
Making a definitive diagnosis of MCS is challenging
Although first described by the allergist Theron G. Randolph in the 1960s, 
no accepted definition of the symptomatology and causes of MCS have been 
established since then [3, 23]. This renders it difficult to make an unequivocal 
diagnosis and frequently leaves non-experts with a feeling of arbitrariness. 
Table 1 shows the 1999 consensus criteria for the definition of MCS published 
by Bartha et al. [24].
Apart from observing these criteria, it is recommended to perform a simul-
taneous biopsychosocial diagnostic evaluation of both somatic and psychosocial 
factors, thus necessitating an interdisciplinary workup of somatic and psychosocial 
causes of the disorder by appropriate specialists [25]. However, the label “MCS” 
should always be used with caution [26].
In addition individuals with MCS 
suffer from perceived stigmatization, 
impaired quality of life and 
psychosocial comorbidities.
As there is no accepted definition 
of MCS and its causes, diagnostic 
classification remains challenging.
Interdisciplinary workup is 
recommended.
Table 1 Consensus criteria for the definition of multiple chemical sensitivity (MCS) (modified after [24]).
1 Symptoms are reproducible with repeat chemical exposure.
2 It is a chronic condition.
3 Symptoms are triggered by low exposure levels that are usually tolerated by other people, or that used to be tolerated 
prior to the onset of the condition.
4 Symptoms improve or abate completely when the triggers are avoided or removed.
5 Symptoms are triggered by various chemically unrelated agents.
6 Symptoms involve multiple organs or organ systems.
a The diagnosis of MCS shall be made If all criteria (1–6) are fulfilled, even if there are other diagnoses (e.g., asthma, aller-
gies, migraine) that lead to fulfillment of some of the criteria.
b MCS is ruled out when all symptoms (entire spectrum) can be explained by a disorder in the patient’s medical history.
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As MCS patients attribute their symptoms to a number of different environ-
mental factors, they consequently also present to a number of different medical 
specialties, including dermatologists as well as environmental medicine, social and 
occupational medicine, psychosomatic medicine, and ENT specialists. Depending 
on the individual complaints, other specialists too may be consulted. Dermatolo-
gists should be familiar with MCS and should be able to diagnose cutaneous sym-
ptoms independently of this condition. Given that MCS is a diagnosis of exclusion, 
physicians must be familiar with and rule out relevant differential diagnoses. As 
it will be necessary to consult with other specialists, patients should be asked to 
release other physicians involved in their treatment from confidentiality [27]. Re-
ferrals to other specialists should always be discussed with the patients [27]. This 
course of action requires empathy and also time, which may be limited in everyday 
clinical practice for economic reasons [28].
Physicians should ask their patients about previous diagnostic tests and tre-
atments [25]. If patients provide prior test results, physicians should use layman’s 
terms to expressly emphasize that these results are normal (if applicable) [27].
In order to be able to treat diseases that are associated with similar symptoms 
and comorbidities, it is useful to run some basic laboratory tests. Moreover, thy-
roid disorders as well as type I and type IV hypersensitivities should be ruled as 
possible causes. The choice of allergy tests should always be guided by the patient’s 
medical history and symptoms in connection with specific or otherwise relevant 
environmental factors. Nonspecific and expensive screening tests should be avoi-
ded [29, 30]. While we frequently see MCS patients in our outpatient clinic who 
have undergone extensive diagnostic testing, these tests often lack any scientific or 
clinical evidence, let alone clinical/therapeutic consequences.
If there is any indication as to other specific environmental disease causes, 
e.g., due to toxic metals (cadmium, mercury), they must be ruled out by approp-
riate diagnostic tests. Biological monitoring requires a medical justification (i.e., 
clinical symptoms or definitive exposure). If this is the case, patients should be 
referred to an environmental medicine specialist for urinalysis to measure levels of 
organic compounds such as polychlorinated biphenyls, halogenated hydrocarbons 
(e.g., hexachlorobenzene, ppDDE), naphthol or hydroxypyrene (air pollution). It 
is important to note that the levels thus determined are reference values and not 
toxicological threshold values. For purely statistical reasons, the values will be 
outside the reference range in some cases. This needs to be explained very clearly, 
otherwise MCS patients will tend to attribute their symptoms to that particular 
environmental agent [31]. However, this is scientifically not justified.
When taking a patient’s biopsychosocial history, it is essential to inquire about 
aspects such as subjective theories regarding the disorder as well as health and 
disease behavior. Whenever there are signs of psychosocial stress, the questions 
should also address issues such as family and social environment, situation at the 
workplace, traumatic events and resources [25].
In cases of suspected mental comorbidity as well as psychosocial impact or 
sequelae caused by the disorder, patients should be referred to an appropriate 
specialist. In order counteract any stigmatizing attitudes towards psychosomatic 
medicine, it is important to explain to patients that mental and physical processes 
in the body develop in parallel and that the distinction between the various medical 
specialties is more a question of language than of science [16]. Supportive psy-
chotherapeutic care is useful, especially given the difficult psychosocial situation 
affected individuals find themselves in.
Counseling by social medicine or occupational medicine specialists is crucial, 
especially in cases where patients can no longer work or otherwise participate in 
Given that MCS is a diagnosis of 
exclusion, physicians must be familiar 
with and rule out relevant differential 
diagnoses.
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social activities due to their condition. Pursuant to the German Social Code (So-
zialgesetzbuch), patients may have their disease recognized as disability (due to 
the high level of impairment) (Article 2 SGB Volume IX) and claim social security 
benefits (Article 4 SGB Volume IX).
If there is evidence of olfactory or respiratory problems, patients should be 
referred to an ENT specialist.
Procedures other than those mentioned above are usually not useful or not 
feasible in the diagnostic workup of patients with MCS. For example, while evalua-
tion of the patient’s sense of smell and olfactory threshold might actually be useful, 
affected individuals will frequently decline such a test due to the various fragrances 
(triggers) contained in the test kit. Moreover, as there is conflicting data regar-
ding this test, it is not considered an evidence-based diagnostic procedure [32]. 
Although provocation studies have shown biosensory measurements to be useful 
in the diagnosis of MCS, they are too complex for everyday practice [12]. Ques-
tionnaire-based methods such as the chemical odor sensitivity scale [33] can help 
identify individuals with increased susceptibility to MCS but are not suitable for 
making a definitive diagnosis. There is as yet no biomarker for MCS [34].
Especially for environment-related symptoms, patients frequently urge physi-
cians to perform further diagnostic tests, many of which are not evidence based. 
As the goal of quaternary prevention is to avoid unnecessary interventions, patients 
must be protected from excessive medical procedures based on the tenet “first, do 
no harm” (primum non nocere). This helps avoid unnecessary diagnostic tests, 
misdiagnoses, excessive treatments as well as mental, social and financial strain 
on the part of affected patients [35]. The diagnostic workup and (making the) 
actual diagnosis always require caution and an interdisciplinary approach to rule 
out other possible disease causes, as this will have real-life consequences for the 
subsequent treatment.
The diagnosis of MCS can only be made following interdisciplinary assess-
ment of the individual case, a consensus-based diagnostic workup and exclusion of 
other causes for the symptoms. There is some controversy as to whether the cor-
rect ICD-10 code for MCS should be T78.4 (“allergy, unspecified”) or rather code 
F45.0 (“somatization disorder”). While the DIMDI institute (German Institute for 
Medical Documentation and Information) codes MCS using code T78.4 in its list 
of diagnoses [36], MCS is also mentioned in the S3 guidelines “Management of 
patients with nonspecific, functional and somatoform physical symptoms” [27].
To date, there are no evidence-based treatment 
recommendations
To date, there are no evidence-based treatment recommendations for MCS. Cuta-
neous symptoms such as pruritus may be addressed with symptomatic treatment 
using basic skin care products. Patients should be expressly advised that their 
symptoms will likely improve but that there is no cause for worry if there is no 
immediate relief [27]. It has proven useful to schedule patients for a follow-up 
appointment two to four weeks later in order to monitor the disease course and 
adjust the treatment approach, if necessary [27]. Besides the treatment of cuta-
neous symptoms and other comorbidities, close cooperation with environmental 
medicine and other specialists should be sought.
Treatment decisions are primarily guided by the severity of the clinical 
presentation and any prognostic factors regarding the future disease course 
(Table 2). For patients with severe clinical symptoms or unfavorable prognostic 
MCS patients must be protected 
from unnecessary diagnostic tests, 
misdiagnoses and excessive treatments.
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Table 2 Tool for assessing disease severity and making treatment decisions (modified after [25, 45]).
Characteristics of mild disease and 
possible favorable factors
Clinical characteristics of severe 
 disease
Warning signs for preventable 
 harmful progression (red flags)
– Few, short-lived symptoms
– Subjective well-being is largely 
 consistent with objective findings
– No or only mild psychosocial burden
– Active coping strategies
– Healthy lifestyle
– Social support
– Favorable conditions at the 
 workplace
– Successful doctor-patient 
 relationship
– Bio-psycho-eco-social approach, 
avoiding disaster scenarios and 
unnecessary measures
– Multiple different symptoms
– Frequent or persistent symptoms
– Dysfunctional perception of health/
disease and dysfunctional behavior
– Significantly reduced  functioning 
(sick leave > 4 weeks, social 
 withdrawal, physical deconditioning
– Moderate-to-severe psychosocial 
stress
– Mental comorbidity
– Difficult doctor-patient relationship




– Severe mental comorbidity 
with  significant impairments in 
 everyday life
– Frequent changes of health 
care  professionals and frequent 
 treatment discontinuations
– Evidence of iatrogenic harmful 
 behavior
 Continue treatment; offer psychoso-
cial care, if necessary; repeat assess-
ment after three months
 Interdisciplinary care by specialist/s 
and psychotherapist
 Immediate initiation of interven-
tions, for example, in a (semi-)inpati-
ent setting at an appropriate facility
factors, treatment in a (semi-)inpatient setting at an appropriate facility should 
be considered.
As most patients perceive avoidance as a particularly useful strategy, this is 
frequently the intervention of first choice [37]. In many cases, however, avoiding 
(the) trigger(s) completely is either impossible or results in significant impairment 
of quality of life. Moreover, as long as there is no scientific evidence that avoidance 
is effective, treatment of MCS should primarily focus on coping strategies in order 
to prevent reinforcement of anxiety [26].
Given our requirements in terms of hygiene and technical standards, achieving 
an entirely “MCS-friendly” environment seems to be next to impossible. Reference 
values can only be lowered so much, and this approach reaches its limits when 
it comes to essential foods and other substances (e.g. cleansing and disinfection 
agents) [38]. At this point, at the latest, patients must use individual measures to 
protect themselves [38].
In a survey, many affected individuals reported that meditation or prayer had 
a positive effect on their symptoms [39]. Dietary changes (rotation diet or dietary 
supplements such as lactobacillus acidophilus or magnesium), air filters, massages, 
acupressure, patient support groups and other measures were considered useful by 
many MCS patients [39]. On the other hand, based on patient reports, pharmaco-
logical treatment had a negative effect on their symptoms [37].
Considering the multitude of hypotheses on the pathogenesis of MCS and the 
large number of organ systems potentially affected, there are many symptomatic 
treatment strategies apart from mere avoidance of possible triggers. All of these 
strategies should be based on an interdisciplinary approach.
Supportive psychosomatic or psychotherapeutic measures, learning relaxati-
on and stress management techniques (e.g. “mindfulness-based stress reduction” 
[40]), and increased physical activity can all improve coping in everyday life and 
lead to enhanced well-being [25].
Treatment should primarily focus on 
coping strategies.
Based on patient reports, relaxation 
techniques, patient support groups, 
air filters and dietary changes have a 
positive effect on MCS symptoms.
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Some authors recommend various combinations of different antioxidants, 
frequently accompanied by “detoxifying” measures [41]. However, these measures 
are not evidence based. Not least because of the varying doses and combinations 
used, it is difficult to evaluate the benefits of individual substances. Treatment 
with a multitude of pills and infusions may lead to “catastrophizing”, thus making 
patients perceive their disorder particularly negatively; this phenomenon is known 
to have a negative impact on the subsequent disease course. One should also keep 
in mind that such treatments place a significant financial strain on patients.
It has been demonstrated that nasal sprays with hyaluronic acid used to treat 
olfactory symptoms can improve the well-being of affected study subjects [42]. 
Transcranial magnetic stimulation has also been shown to improve the symptom 
burden, while having no effects on functional impairment [43].
If MCS is regarded as a somatoform or functional disorder, it may be 
treated accordingly [44]. For treatment of functional physical symptoms, physi-
cians from all medical specialties are recommended to observe the S3 guidelines 
“Management of Patients with Nonspecific, Functional and Somatoform Physical 
Symptoms” [27].
If patients demand additional treatments that are not evidence based and 
may do more harm than good, readily understandable language should be used to 
explain to them why these interventions will not have the desired effects.
Medical skills beyond diagnosis and treatment: 
listening and taking symptoms seriously
Irrespective of the various – and anything but clear-cut – options for diagnosis and 
treatment, caring for MCS patients requires that physicians have certain ‘soft skills’. 
In particular, patients with a condition that has no known cause and no definitive 
diagnostic and therapeutic options are greatly affected by this uncertainty and 
are therefore susceptible to mental sequelae. It is the responsibility of physicians 
of all specialties to take these patients seriously, build a trusting doctor-patient 
relationship and to relieve them of the fear of harmful developments, without 
belittling or negating their symptoms [27]. It is important that physicians listen 
to their patients carefully and attentively, without interrupting them during the 
first phase of the interview [27]. The physician’s communicative and psychosocial 
skills are therefore particularly important; additional psychotherapeutic expertise 
is likewise useful (Table 3).
When talking to affected individuals, physicians should exhibit an actively 
supportive attitude and use language that is readily understood by lay persons. If 
necessary, one should actively ensure that the patient has understood the infor-
mation given. Stigmatizing or catastrophizing communication must be avoided in 
Scientific studies have shown that 
psychotherapeutic support, nasal 
sprays with hyaluronic acid and 
transcranial magnetic stimulation 
may improve the well-being of 
patients with MCS.
When talking to affected individuals, 
physicians should exhibit an 
actively supportive attitude and use 
language that is readily understood 
by lay persons.
Table 3 Medical skills according to Egger (2017) [16].
Mandatory communication 
( psychosocial) skills
Mandatory skills in natural science Special skills in psychotherapy
Professional doctor-patient communi-
cation; promoting a bio-psycho-eco- 
social understanding of the condition
Knowledge of and skills in bio-medical 
interventions and surgical options
Knowledge of and psychological skills 
in the management of behavioral 
risk factors; actively and supportively 
helping patients to help themselves; 
resource orientation
CME-Article
126 © 2020 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft. | JDDG | 1610-0379/2020/1802
order to build a positive doctor-patient relationship [45]. If the medical history and 
clinical findings do not yield any evidence for a preventable and potentially harm-
ful progression of known physical or mental diseases, this should be immediately 
communicated and explained to the patient, using clear and readily understandab-
le language [27]. Patients should be involved in setting incremental, realistic treat-
ment goal such as improved well-being, or increased physical or social activity [27].
Advanced medical education courses available to dermatologists in this con-
text include courses on “basic psychosomatic care”. Communication training is 
another option to improve their skills in effectively communicating with and ma-
naging MCS patients.
Conclusions
Patients with MCS respond to even very small levels of environmental agents and 
present with a wide range of nonspecific symptoms. As the skin may also be affec-
ted, for example, in the form of pruritus, dermatologists will be confronted with 
this disorder in everyday clinical practice.
Establishing a definitive classification of MCS remains a challenge due to our 
insufficient understanding of its pathogenesis and particularly due to the lack of 
objective, evidence-based biomarkers. Thus, MCS is a diagnosis of exclusion. It is 
up to the dermatologist to investigate and, if needed, treat any skin diseases and 
hypersensitivities that may be the cause of the patient’s symptoms. To date, there is 
no evidence-based treatment for MCS.
Exactly for this reason, interdisciplinary cooperation in both diagnosis and 
treatment is just as important for MCS patients as treating any cutaneous symp-
toms, for example, by using basic skin care products. Communication skills on the 
part of physicians are essential, and patients’ symptoms have to be taken seriously.
Science needs to comply with the demands of those affected and investigate the 
effects of anthropogenic agents on the human body in greater detail. In the course 
of these investigations, scientists also need to clarify whether MCS is primarily a 
psychosomatic, a somato-psychological, or a “circular” disorder. In the future, this 
may offer new options for diagnosis and treatment of MCS.
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Lernerfolgskontrolle
1. Mögliche protektive Faktoren, die 
gegen einen schweren Krankheitsver-
lauf sprechen sind:
 1.  aktive Bewältigungsstrategien (zum 
Beispiel körperliches Training, positi-
ve Lebenseinstellung, Motivation für 
 Psychotherapie)
 2.  deutlich reduzierte Funktionsfähig-
keit; Arbeitsunfähigkeit > 4 Wochen, 
sozialer Rückzug
 3.  gelingende Behandler- Patient-
Beziehung
 4.  biopsychosozialer, entkatastrophi-
sierender Ansatz unter Vermeidung 
unnötiger  Maßnahmen
 5.  dysfunktionale Gesundheits-/
Krankheitswahrnehmung
a) Alle sind richtig.
b) Es gibt keine protektiven Faktoren.
c) Schwere Krankheitsverläufe sind 
immer zu erwarten, da es sich um 
eine chronische Krankheit handelt.
d) 1, 3, 5 sind richtig.
e) 1, 3, 4 sind richtig.
2. Welche Aussage zur 
MCS-Symptomatik ist richtig?
Symptom/e der MCS ist/sind …
a) Symptome eines Organsystems.
b) eine mehrtägige Verzögerung 
der Symptomatik nach geringer 
 Exposition.
c) eine positive Familienanamnese zu 
Anosmie.
d) unspezifische Beschwerden bei 
Kontakt gegenüber verschiedenen 
Stoffen aus der Umwelt.
e) eine Kontaktallergie zu einem 
Metall.
3. Welche Aussage zur Diagnostik 
von MCS ist richtig?
a) MCS-Diagnostik sollte nur bei 
drohender Berufsunfähigkeit 
erfolgen.
b) Nach einer gründlichen biopsy-
chosozialen Anamnese kann in den 
meisten Fällen auf eine somatische 
Diagnostik verzichtet werden.
c) Fremdanamnesen sind bei MCS 
schwerer zu gewichten als 
Eigenanamnesen.
d) Die umfassende Umweltanalytik 
im Urin ist der Goldstandard in der 
Diagnosefindung.
e) Die MCS-Diagnose ist eine 
Ausschlussdiagnose, für die es keine 
validierten Biomarker gibt.
4. Welche Aussage zu MCS ist 
richtig?
a) Die Therapie der MCS-Symptoma-
tik erfolgt ausschließlich durch die 
Dermatologie.
b) Zur Behandlung von MCS sind vor 
allem chirurgische Kompetenzen 
notwendig.
c) Eine aktiv unterstützende Grundhal-
tung hilft dabei, eine vertrauensvolle 
Beziehung mit MCS-Patient*innen 
oder Menschen mit MCS aufzubauen.
d) Anstatt kleinschrittige Ziele zu 
vereinbaren, sollte immer die 
vollständige Heilung von MCS im 
Vordergrund stehen.
e) MCS ist eine Modekrankheit und 
muss deshalb nicht ernst genom-
men werden.
5. Welche Aussage zur Therapie 
von MCS ist richtig?
a) Pharmakologische Therapie hat 
sich zur Behandlung der MCS als 
wirksam erwiesen.
b) Die Therapie von MCS gestaltet sich 
für jeden Fall gleich.
c) Betroffene fordern häufig 
psychotherapeutische Begleitung, 
obwohl diese nicht evidenzbasiert 
ist.
d) Diagnosestellung und Therapie 
sollten erst nach interdisziplinärer 
Absprache erfolgen.
e) Eine Vermeidungsstrategie 
wird als erste Therapieoption 
empfohlen.
6. Welche Aussage zu MCS ist 
richtig?
a) MCS ist keine Behinderung nach 
dem SGB IX.
b) Rehabilitationsmaßnahmen können 
von den Krankenkassen übernom-
men werden.
c) Eine sozialmedizinische Einbindung 
ist nur bei zusätzlicher Komorbidität 
sinnvoll.
d) Eine (teil-)stationäre Behandlung ist 
bei einer chronischen Erkrankung 
wie der MCS nicht indiziert.
e) Eine chemikalienarme Umgebung 
ist ungünstig, da wiederholte 
Provokation die Reizschwelle erhöht.
7. Welche Aussage zu 
MCS- Patienten ist falsch?
a) Die geschätzte Prävalenz von 
diagnostizierten MCS-Fällen in 
Deutschland beträgt circa 0,5 %.
b) Eine MCS kann auch bei Betroffe-
nen ohne Kenntnis über die initial 
auslösende Exposition diagnostiziert 
werden.
c) Fragebögen sind nicht zur 
Diagnostik von MCS geeignet.
d) MCS-Patient*innen haben selten 
Kontakt zu multiplen Ärzt*innen, 
sondern gehen direkt in entspre-
chende Umweltambulanzen.
e) MCS-Patient*innen präsentie-
ren sich häufig mit polymorpher 
Symptomatik.
8. Welche Aussage ist zu MCS ist 
falsch?
a) MCS ist eine Berufserkrankung.
b) Es wird kontrovers diskutiert, ob 
MCS nach ICD-10 als T78.4 oder 
F45.0 zu kodieren ist.
c) MCS wird von den gesetzlichen 
Krankenkassen anerkannt.
d) MCS steht für multiple Chemikalien-
sensibilität und wird mit „idiopathi-
scher Umwelttoleranz“ beziehungs-
weise Idiopathic Environmental 
Illness (IEI) synonym verwendet.
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e) MCS führt in schweren Fällen zur 
sozialen Isolation durch Unverständ-
nis im Umfeld und zu Vermeidungs-
verhalten aus Angst vor Triggerex-
position.
9. Welche Aussage zu MCS ist 
falsch?
a) Bei Herz-Kreislauf-Symptomatik ist 
eine kardiologisch-internistische 
Abklärung ratsam.
b) Bei dermatologischen Beschwerden, 
die der Patient mit einer Umweltex-
position in Zusammenhang bringt, 
ist eine rasche Überweisung an die 
Psychosomatik ratsam.
c) Ein Patchtest ist bei Hinweisen auf 
eine Sensibilisierung durch Metalle 
ein valides Diagnosemittel.
d) Dermatologische Beschwerden bei 
MCS treten häufig in Form trockener 
Haut, Rubeosis faciei und Pruritus 
auf.
e) Missempfindungen, vor allem des 
Geruchs- und Geschmackssinns, 
können Symptome einer MCS sein.
10. Welche Aussage zur Pathophy-
siologie ist falsch?
a) MCS könnte durch eine klassische 
Konditionierung auf olfaktorische 
Reize entstehen.
b) In allen Studien kristallisiert sich 
eine niedrigere Geruchsschwelle 
und eine höhere Diskriminations-
fähigkeit zwischen Duftstoffen der 
MCS-Patient*innen heraus.
c) Eine Hypothese zur Pathogenese 
von MCS ist der toxisch bedingte 
Toleranzverlust.
d) Zu den auslösenden Umweltstoffen 
zählen unter anderem Schwer-
metalle, Desinfektionsmittel und 
Duftstoffe.
e) MCS kann nach kurzeitiger 
Exposition einer hohen Dosis und 
nach langzeitiger Exposition einer 
niedrigen Dosis eines auslösenden 
Umweltstoffs entstehen.
Liebe Leserinnen und Leser,
der Einsendeschluss an die DDA für  
diese Ausgabe ist der 13. März 2020.  
Die richtige Lösung zum Thema  
„Eosinophile Hautkrankheiten“ in Heft 
10  (Oktober 2019) ist: (1e, 2c, 3b, 4c, 5c, 
6b, 7e, 8c, 9e, 10c). 
Bitte verwenden Sie für Ihre Einsen-
dung das aktuelle Formblatt auf der 
folgenden Seite oder aber geben Sie 
Ihre Lösung online unter http://jddg.
akademie-dda.de ein.
